Lymphatic Filariasis Clinical Trials

Find Lymphatic Filariasis Clinical Trials Near You

Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are: 1. Does MoxDA clear infection in people with lymphatic filariasis ? 2. Does MoxDA cause any medical problems in infected and uninfected people? Researchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems. Participants will: 1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis 2. Take 3 single doses of MoxDA or IDA, 12 months apart 3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• Provision of signed and dated informed consent.

• Resident in one of the study locations.

Locations
Other Locations
Fiji
Ministry of Health and Medical Services Fiji
RECRUITING
Suva
Time Frame
Start Date: 2026-09-28
Estimated Completion Date: 2028-06
Participants
Target number of participants: 5100
Treatments
Experimental: MoxDA
Moxidectin + diethylcarbamazine + albendazole
Active_comparator: IDA
Ivermectin + diethylcarbamazine + albendazole
Sponsors
Leads: Medicines Development for Global Health
Collaborators: Murdoch Childrens Research Institute, Kirby Institute

This content was sourced from clinicaltrials.gov